Fortune India 500 2025 edition
Rank#83- Total income
- ₹34,308 Cr
- Profit
- ₹5,655 Cr
Last year #85
Dr.Reddy's Laboratories Ltd - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
Active Listed - NSE: DRREDDY · BSE: 500124 Public Limited Company pharma Fortune India 500 · #83 India's Most Valuable Nifty 50
Market Cap
₹1,03,876 Cr
DRREDDY · NSE
Share Price
₹1,239.00
-0.44% today
Revenue
₹33,700 Cr
FY 2025-26 · +3.2% YoY
EBITDA
₹6,454 Cr
Margin 19.1%
Net Profit
₹4,007 Cr
FY 2025-26 · -27.8% YoY
P/E (TTM)
32.2x
P/B 2.7x
ROE
11.6%
ROCE 13.7%
Debt / Equity
0.17
Interest cover 8.5x
About Dr.Reddy's Laboratories Ltd
Data last updated:
Dr.Reddy's Laboratories Ltd is a public limited company based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 24 February 1984 and has been in existence for over 42 years.
Dr.Reddy's Laboratories is ranked #83 on the Fortune India 500 (2025). It is part of the Nifty 50, Nifty 500 and BSE 500 indices. Its director K Satish Reddy and family are #223 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L85195TG1984PLC004507. Its GSTIN is 36AAACD7999Q1ZL (Telangana). The company holds 35 GST registrations, of which 24 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 500124 and NSE: DRREDDY.
The company has an authorised share capital of ₹145 Cr and a paid-up capital of ₹83.47 Cr. It was formerly known as Dr.Reddy'S Laboratories P Ltd. It is led by directors including Venkateswara Prasad Gunupati (Managing Director) and Satish Reddy Kallam (Whole-Time Director).
Its last annual general meeting (AGM) was held on 23 July 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 8 – 2 – 337 Road No. 3 Banjara Hills, Hyderabad, Telangana, India – 500034.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹33,700 Cr, a growth of 3.2% compared to the previous year. For the same year it recorded a net profit of ₹4,007.16 Cr (net margin 11.9%) and EBITDA of ₹6,453.5 Cr (EBITDA margin 19.1%). The net worth stands at ₹37,892 Cr (up 12.9% YoY). Total assets are valued at ₹46,343 Cr (up 19.2% YoY).
The company has about 7,985 employees on its provident fund (EPFO) records. Its group structure includes 9 subsidiaries and 1 joint venture.
The company is associated with 3 brands: Aurigene, Studio 5b and Dr. Reddy's Laboratories. As per MCA filings, the company has open charges of ₹34.23 Cr and satisfied charges of ₹586.71 Cr on record. Court records list 730 cases involving the company, including 485 filed by the company and 247 filed against it; 192 cases are pending. The company has 72 deals on record (61 market trades, 4 secondary share transfers, 4 acquisitions), with disclosed funding of ₹630 Cr; the latest was in September 2025. Its 6 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 1 larger and 5 smaller; the largest is Sun Pharmaceutical Industries Limited with revenue of ₹54,543 Cr. The company has 102 MSME Form 1 returns on record between 2008 and 2024, listing 879 overdue payments to 93 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website drreddys.com.
Company details
CIN L85195TG1984PLC004507
Registration Number 004507
Incorporation Date 24 February 1984
ROC Hyderabad
Listing Status Listed - Listed on NSE (DRREDDY); Listed on BSE (500124)
Company Status Active
Date of Last AGM 23 July 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
CIN history
Dr.Reddy's Laboratories has one previous CIN (Corporate Identification Number): L85195AP1984PLC004507. The current CIN is L85195TG1984PLC004507, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L85195TG1984PLC004507 | Current |
| L85195AP1984PLC004507 | Previous |
Key People
Erez Israeli Ceo Venkateswara Prasad Gunupati Managing Director Satish Reddy Kallam Whole-Time Director Recognitions & Rankings of Dr.Reddy's Laboratories
India's Most Valuable Companies 2025 edition · Source: Hurun India
- Valuation
- ₹1,10,420 Cr
2024 #61 2023 #47 2022 #54
India's Richest People 2026 edition · 1 director · Source: Hurun India
- #223 K Satish Reddy & family ₹16,700 Cr
Stock market indices
Nifty 50 Nifty 500 BSE 500
Contact details
Dr.Reddy's Laboratories Ltd's registered office is in Hyderabad, Telangana. Its website is drreddys.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address8 – 2 – 337 Road No. 3 Banjara Hills, Hyderabad, Telangana, India – 500034
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Dr.Reddy's Laboratories Ltd, buy the company report.
Comprehensive company report
Dr.Reddy's Laboratories Ltd - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Dr.Reddy's Laboratories operates multiple associated brands including Aurigene, Studio 5b, and Dr. Reddy's Laboratories. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Discovers and develops novel oncology therapeutics via research collaborations. | aurigene.com | |
| Innovative medicines are developed and manufactured globally by the company. | drreddys.com | |
| Design of people-centric healthcare solutions globally. | studio-5b.com |
Business activity
The main business activity of Dr.Reddy's Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Dr.Reddy's Laboratories Ltd, buy the company report.
Financials of Dr.Reddy's Laboratories Ltd
FY 2025-26 filings availableDr.Reddy's Laboratories Ltd reported revenue of ₹33,700 Cr (up 3.2% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹33,700 Cr
+3.2% YoY
EBITDA
₹6,454 Cr
-24.5% YoY
Profit After Tax
₹4,007 Cr
-27.8% YoY
Net Worth
₹37,892 Cr
+12.9% YoY
Total Assets
₹46,343 Cr
+19.2% YoY
Total Debt
₹7,734 Cr
+65.4% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 33,700 | 32,644 | 28,011 | 24,670 | 21,545 | 19,048 | 17,517 |
| Revenue growth | +3.2% | +16.5% | +13.5% | +14.5% | +13.1% | +8.7% | - |
| EBITDA | 6,454 | 8,547 | 7,933 | 6,349 | 3,768 | 3,870 | 2,470 |
| EBITDA margin | +19.2% | +26.2% | +28.3% | +25.7% | +17.5% | +20.3% | +14.1% |
| Profit before tax | 5,393 | 7,680 | 7,201 | 6,048 | 3,061 | 2,884 | 1,886 |
| Net profit | 4,007 | 5,548 | 5,512 | 4,598 | 2,111 | 1,954 | 2,030 |
| Net profit margin | +11.9% | +17.0% | +19.7% | +18.6% | +9.8% | +10.3% | +11.6% |
| EPS (₹) | 50.25 | 67.81 | 334.41 | 270.55 | 131.16 | 117.28 | 121.90 |
| Balance sheet | |||||||
| Total assets | 46,343 | 38,879 | 30,595 | 24,856 | 22,790 | 20,885 | 18,089 |
| Net worth | 37,892 | 33,550 | 28,255 | 23,286 | 19,212 | 17,642 | 15,599 |
| Total debt | 7,734 | 4,677 | 2,002 | 1,347 | 3,384 | 3,031 | 2,210 |
| Cash & bank | 3,349 | 2,460 | 1,728 | 1,730 | 2,419 | 2,079 | 205 |
| Net working capital | 16,122 | 12,544 | 12,215 | 8,623 | 8,809 | 7,469 | 5,096 |
| Cash flow | |||||||
| Cash from operations | 5,674 | 4,643 | 4,543 | 5,888 | 2,811 | 3,570 | 2,984 |
| Cash from investing | (6,425) | (5,785) | (4,034) | (4,109) | (2,565) | (2,255) | (495) |
| Cash from financing | 829 | 1,891 | (376) | (2,686) | (242) | (29.80) | (2,516) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8,100 | 7,546 | 8,753 | 8,828 | 8,572 | 8,528 | 8,381 | 8,038 |
| Revenue growth (YoY) | -5.5% | -11.5% | +4.4% | +9.8% | +11.4% | - | - | - |
| Other income | 356 | 480 | 271 | 330 | 290 | 528 | 154 | 314 |
| EBITDA | 860 | 382 | 1,888 | 2,010 | 2,174 | 1,998 | 2,273 | 2,076 |
| EBITDA margin | +10.7% | +5.1% | +21.6% | +22.8% | +25.4% | +23.5% | +27.2% | +25.9% |
| Depreciation | 537 | 557 | 521 | 505 | 476 | 455 | 471 | 397 |
| Interest | 126 | 106 | 94.40 | 90.70 | 83.00 | 65.60 | 81.70 | 75.70 |
| Profit before tax | 553 | 200 | 1,543 | 1,745 | 1,905 | 2,005 | 1,874 | 1,917 |
| Tax | 118 | (21.60) | 354 | 408 | 495 | 418 | 470 | 576 |
| Net profit | 436 | 221 | 1,190 | 1,337 | 1,410 | 1,587 | 1,404 | 1,342 |
| EPS (₹) | 5.33 | 2.65 | 14.52 | 16.18 | 17.02 | 19.10 | 16.94 | 75.25 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 20,533 | 23,115 | 19,484 | 16,962 | 14,405 | 13,349 | 11,850 |
| Revenue growth | -11.2% | +18.6% | +14.9% | +17.8% | +7.9% | +12.7% | - |
| EBITDA | 3,917 | 7,382 | 5,926 | 4,215 | 2,594 | 3,137 | 2,870 |
| EBITDA margin | +19.1% | +31.9% | +30.4% | +24.9% | +18.0% | +23.5% | +24.2% |
| Profit before tax | 4,251 | 7,236 | 5,791 | 3,866 | 2,224 | 3,056 | 2,776 |
| Net profit | 3,063 | 5,381 | 4,284 | 2,629 | 1,629 | 1,849 | 2,949 |
| Net profit margin | +14.9% | +23.3% | +22.0% | +15.5% | +11.3% | +13.9% | +24.9% |
| EPS (₹) | 38.56 | 64.14 | 260.31 | 156.83 | 97.55 | 131.39 | 176.76 |
| Balance sheet | |||||||
| Total assets | 37,357 | 32,540 | 25,148 | 20,618 | 20,636 | 18,266 | 16,733 |
| Net worth | 31,366 | 28,857 | 24,241 | 20,474 | 18,336 | 16,984 | 15,192 |
| Total debt | 5,737 | 3,493 | 793 | 50.80 | 2,205 | 1,214 | 1,457 |
| Cash & bank | 1,958 | 977 | 1,217 | 646 | 2,030 | 1,646 | 39.20 |
| Net working capital | 9,634 | 8,385 | 8,903 | 5,073 | 7,720 | 6,324 | 5,245 |
| Cash flow | |||||||
| Cash from operations | 4,660 | 4,225 | 3,450 | 5,053 | 1,339 | 3,514 | 1,839 |
| Cash from investing | (5,760) | (5,697) | (3,429) | (3,403) | (1,990) | (1,454) | (1,689) |
| Cash from financing | 1,117 | 1,591 | 68.10 | (2,697) | 506 | (794) | (224) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5,137 | 3,822 | 4,283 | 4,619 | 7,810 | 5,563 | 5,015 | 6,696 |
| Revenue growth (YoY) | -34.2% | -31.3% | -14.6% | -31.0% | +33.7% | - | - | - |
| Other income | 440 | 567 | 360 | 364 | 398 | 414 | 235 | 208 |
| Total expenses | 4,689 | 4,322 | 4,183 | 4,138 | 3,972 | 4,120 | 3,823 | 3,975 |
| EBITDA | 447 | (500) | 99.60 | 480 | 3,837 | 1,443 | 1,192 | 2,722 |
| EBITDA margin | +8.7% | -13.1% | +2.3% | +10.4% | +49.3% | +26.0% | +23.9% | +40.7% |
| Depreciation | 318 | 318 | 314 | 295 | 280 | 264 | 265 | 260 |
| Interest | 73.10 | 54.30 | 41.40 | 33.40 | 19.20 | 31.10 | 43.30 | 28.40 |
| Profit before tax | 497 | (306) | 104 | 516 | 3,936 | 1,562 | 1,119 | 2,641 |
| Tax | 92.30 | (86.10) | 13.60 | 129 | 975 | 361 | 270 | 759 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 22 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8,100 | 7,546 | 8,753 | 8,828 | 8,572 | 8,528 | 8,381 | 8,038 |
| Revenue growth (YoY) | -5.5% | -11.5% | +4.4% | +9.8% | +11.4% | - | - | - |
| Other income | 356 | 480 | 271 | 330 | 290 | 528 | 154 | 314 |
| EBITDA | 860 | 382 | 1,888 | 2,010 | 2,174 | 1,998 | 2,273 | 2,076 |
| EBITDA margin | +10.7% | +5.1% | +21.6% | +22.8% | +25.4% | +23.5% | +27.2% | +25.9% |
| Depreciation | 537 | 557 | 521 | 505 | 476 | 455 | 471 | 397 |
| Interest | 126 | 106 | 94.40 | 90.70 | 83.00 | 65.60 | 81.70 | 75.70 |
| Profit before tax | 553 | 200 | 1,543 | 1,745 | 1,905 | 2,005 | 1,874 | 1,917 |
| Tax | 118 | (21.60) | 354 | 408 | 495 | 418 | 470 | 576 |
| Net profit | 436 | 221 | 1,190 | 1,337 | 1,410 | 1,587 | 1,404 | 1,342 |
| EPS (₹) | 5.33 | 2.65 | 14.52 | 16.18 | 17.02 | 19.10 | 16.94 | 75.25 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 33,700 | 32,644 | 28,011 | 24,670 | 21,545 | 19,048 | 17,517 |
| Revenue growth | +3.2% | +16.5% | +13.5% | +14.5% | +13.1% | +8.7% | - |
| Other income | 1,372 | 1,119 | 909 | 1,092 | 555 | 339 | 677 |
| Total expenses | 27,247 | 24,097 | 20,078 | 18,321 | 17,778 | 15,178 | 15,047 |
| Employee cost | 5,991 | 5,580 | 5,030 | 4,647 | 3,886 | 3,630 | 3,380 |
| EBITDA | 6,454 | 8,547 | 7,933 | 6,349 | 3,768 | 3,870 | 2,470 |
| EBITDA margin | +19.2% | +26.2% | +28.3% | +25.7% | +17.5% | +20.3% | +14.1% |
| Depreciation | 2,059 | 1,704 | 1,470 | 1,250 | 1,165 | 1,229 | 1,163 |
| Interest | 374 | 283 | 171 | 143 | 95.80 | 97.00 | 98.30 |
| Profit before tax | 5,393 | 7,680 | 7,201 | 6,048 | 3,061 | 2,884 | 1,886 |
| Tax | 1,235 | 1,954 | 1,623 | 1,541 | 879 | 932 | (140) |
| Net profit | 4,007 | 5,548 | 5,512 | 4,598 | 2,111 | 1,954 | 2,030 |
| Net profit margin | +11.9% | +17.0% | +19.7% | +18.6% | +9.8% | +10.3% | +11.6% |
| EPS (₹) | 50.25 | 67.81 | 334.41 | 270.55 | 131.16 | 117.28 | 121.90 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 83.50 | 83.40 | 83.40 | 83.30 | 83.20 | 83.20 | 83.10 |
| Reserves & surplus | 37,990 | 33,693 | 28,171 | 23,330 | 19,289 | 17,755 | 15,616 |
| Shareholders' funds (net worth) | 37,892 | 33,550 | 28,255 | 23,286 | 19,212 | 17,642 | 15,599 |
| Minority interest | 339 | 378 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 179 |
| Unsecured loans | 7,734 | 4,677 | 2,002 | 1,347 | 3,384 | 3,031 | 2,032 |
| Total debt | 7,734 | 4,677 | 2,002 | 1,347 | 3,384 | 3,031 | 2,210 |
| Total liabilities | 46,343 | 38,879 | 30,595 | 24,856 | 22,790 | 20,885 | 18,089 |
| Assets | |||||||
| Gross block | 43,854 | 36,760 | 28,062 | 25,567 | 23,096 | 18,556 | 16,108 |
| Net block | 22,063 | 18,226 | 10,426 | 9,219 | 8,122 | 8,206 | 6,850 |
| Capital work in progress | 1,460 | 2,466 | 1,419 | 1,030 | 1,293 | 1,565 | 1,535 |
| Investments | 5,285 | 4,051 | 4,930 | 4,986 | 2,616 | 2,212 | 2,678 |
| Inventories | 7,653 | 7,108 | 6,355 | 4,867 | 5,088 | 4,541 | 3,507 |
| Sundry debtors | 10,123 | 9,042 | 8,030 | 7,248 | 6,676 | 4,964 | 5,028 |
| Cash & bank balances | 3,349 | 2,460 | 1,728 | 1,730 | 2,419 | 2,079 | 205 |
| Loans & advances | 5,230 | 3,077 | 4,288 | 2,130 | 1,581 | 1,588 | 1,491 |
| Total current assets | 26,356 | 21,687 | 20,400 | 15,976 | 15,765 | 13,172 | 10,230 |
| Total current liabilities | 10,234 | 9,144 | 8,185 | 7,353 | 6,956 | 5,703 | 5,134 |
| Net working capital | 16,122 | 12,544 | 12,215 | 8,623 | 8,809 | 7,469 | 5,096 |
| Total assets | 46,343 | 38,879 | 30,595 | 24,856 | 22,790 | 20,885 | 18,089 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1,459 | 711 | 578 | 1,485 | 1,482 | 196 | 223 |
| Net cash from operating activities | 5,674 | 4,643 | 4,543 | 5,888 | 2,811 | 3,570 | 2,984 |
| Net cash from investing activities | (6,425) | (5,785) | (4,034) | (4,109) | (2,565) | (2,255) | (495) |
| Net cash from financing activities | 829 | 1,891 | (376) | (2,686) | (242) | (29.80) | (2,516) |
| Net change in cash | 77.50 | 749 | 133 | (907) | 3.20 | 1,286 | (26.60) |
| Closing cash | 3,349 | 2,460 | 1,728 | 1,730 | 2,419 | 2,079 | 205 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +3.2% | +16.5% | +13.5% | +14.5% | +13.1% | +8.7% | - |
| EBITDA growth | -24.5% | +7.7% | +25.0% | +68.5% | -2.6% | +56.7% | - |
| PBT growth | -29.8% | +6.6% | +19.1% | +97.6% | +6.2% | +52.9% | -19.3% |
| Net income growth | -27.8% | +0.7% | +19.9% | +117.8% | +8.0% | -3.7% | - |
| Revenue CAGR (3Y) | +11.0% | +14.9% | +13.7% | +12.1% | +11.7% | +10.1% | +7.3% |
| EBITDA CAGR (3Y) | +0.6% | +31.4% | +27.0% | +37.0% | +5.8% | +18.1% | -0.0% |
| Profitability & leverage | |||||||
| Net income margin | +12.3% | +17.5% | +19.9% | +18.3% | +10.1% | +10.3% | +11.6% |
| Return on capital employed | +13.7% | +23.1% | +26.6% | +26.0% | +14.5% | +15.3% | +11.0% |
| Return on net worth | +11.6% | +18.5% | +21.6% | +21.2% | +11.8% | +11.7% | +13.7% |
| Debt / equity | 0.17 | 0.11 | 0.06 | 0.11 | 0.17 | 0.16 | 0.20 |
| Long-term debt / equity | 0.03 | 0.02 | 0.01 | 0.02 | 0.03 | 0.02 | 0.08 |
| Interest cover | 8.51 | 4.13 | 2.65 | 2.80 | 3.68 | 3.67 | 7.52 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.84 | 1.01 | 1.04 | 1.01 | 1.03 | 1.10 | 1.13 |
| Inventory turnover | 4.57 | 4.85 | 4.99 | 4.96 | 4.47 | 4.73 | 5.10 |
| Debtors turnover | 3.52 | 3.82 | 3.67 | 3.54 | 3.70 | 3.81 | 3.89 |
| EPS (₹) | 50.25 | 67.81 | 334.41 | 270.55 | 131.16 | 117.28 | 121.90 |
| Dividend per share (₹) | 8.00 | 8.00 | 40.00 | 40.00 | 30.00 | 25.00 | 25.00 |
| Book value per share (₹) | 455.96 | 404.99 | 1,693.93 | 1,405.34 | 1,164.21 | 1,072.02 | 944.61 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5,137 | 3,822 | 4,283 | 4,619 | 7,810 | 5,563 | 5,015 | 6,696 |
| Revenue growth (YoY) | -34.2% | -31.3% | -14.6% | -31.0% | +33.7% | - | - | - |
| Other income | 440 | 567 | 360 | 364 | 398 | 414 | 235 | 208 |
| Total expenses | 4,689 | 4,322 | 4,183 | 4,138 | 3,972 | 4,120 | 3,823 | 3,975 |
| EBITDA | 447 | (500) | 99.60 | 480 | 3,837 | 1,443 | 1,192 | 2,722 |
| EBITDA margin | +8.7% | -13.1% | +2.3% | +10.4% | +49.3% | +26.0% | +23.9% | +40.7% |
| Depreciation | 318 | 318 | 314 | 295 | 280 | 264 | 265 | 260 |
| Interest | 73.10 | 54.30 | 41.40 | 33.40 | 19.20 | 31.10 | 43.30 | 28.40 |
| Profit before tax | 497 | (306) | 104 | 516 | 3,936 | 1,562 | 1,119 | 2,641 |
| Tax | 92.30 | (86.10) | 13.60 | 129 | 975 | 361 | 270 | 759 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 20,533 | 23,115 | 19,484 | 16,962 | 14,405 | 13,349 | 11,850 |
| Revenue growth | -11.2% | +18.6% | +14.9% | +17.8% | +7.9% | +12.7% | - |
| Other income | 1,690 | 1,003 | 862 | 591 | 482 | 801 | 743 |
| Total expenses | 16,615 | 15,734 | 13,557 | 12,748 | 11,811 | 10,212 | 8,981 |
| Employee cost | 3,550 | 3,288 | 3,086 | 2,833 | 2,435 | 2,270 | 2,030 |
| EBITDA | 3,917 | 7,382 | 5,926 | 4,215 | 2,594 | 3,137 | 2,870 |
| EBITDA margin | +19.1% | +31.9% | +30.4% | +24.9% | +18.0% | +23.5% | +24.2% |
| Depreciation | 1,207 | 1,039 | 976 | 923 | 814 | 835 | 789 |
| Interest | 148 | 110 | 21.80 | 16.90 | 38.00 | 46.70 | 47.80 |
| Profit before tax | 4,251 | 7,236 | 5,791 | 3,866 | 2,224 | 3,056 | 2,776 |
| Tax | 1,032 | 1,886 | 1,449 | 1,253 | 601 | 870 | (162) |
| Net profit | 3,063 | 5,381 | 4,284 | 2,629 | 1,629 | 1,849 | 2,949 |
| Net profit margin | +14.9% | +23.3% | +22.0% | +15.5% | +11.3% | +13.9% | +24.9% |
| EPS (₹) | 38.56 | 64.14 | 260.31 | 156.83 | 97.55 | 131.39 | 176.76 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 83.50 | 83.40 | 83.40 | 83.30 | 83.20 | 83.20 | 83.10 |
| Reserves & surplus | 31,464 | 29,000 | 24,157 | 20,518 | 18,413 | 17,097 | 15,209 |
| Shareholders' funds (net worth) | 31,366 | 28,857 | 24,241 | 20,474 | 18,336 | 16,984 | 15,192 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.30 |
| Unsecured loans | 5,737 | 3,493 | 793 | 50.80 | 2,205 | 1,214 | 1,438 |
| Total debt | 5,737 | 3,493 | 793 | 50.80 | 2,205 | 1,214 | 1,457 |
| Total liabilities | 37,357 | 32,540 | 25,148 | 20,618 | 20,636 | 18,266 | 16,733 |
| Assets | |||||||
| Gross block | 21,344 | 17,715 | 16,297 | 15,137 | 13,349 | 12,345 | 10,216 |
| Net block | 10,730 | 8,232 | 7,589 | 7,195 | 6,150 | 5,844 | 4,434 |
| Capital work in progress | 1,369 | 2,197 | 1,211 | 924 | 1,200 | 901 | 412 |
| Investments | 15,595 | 13,194 | 7,321 | 7,440 | 4,937 | 4,649 | 5,486 |
| Inventories | 4,956 | 4,576 | 4,019 | 3,043 | 3,348 | 2,820 | 2,190 |
| Sundry debtors | 4,119 | 5,959 | 4,624 | 4,289 | 4,945 | 4,080 | 4,639 |
| Cash & bank balances | 1,958 | 977 | 1,217 | 646 | 2,030 | 1,646 | 39.20 |
| Loans & advances | 4,258 | 2,108 | 3,838 | 1,513 | 1,255 | 1,141 | 1,120 |
| Total current assets | 15,290 | 13,620 | 13,698 | 9,490 | 11,579 | 9,687 | 7,988 |
| Total current liabilities | 5,656 | 5,235 | 4,795 | 4,418 | 3,859 | 3,364 | 2,743 |
| Net working capital | 9,634 | 8,385 | 8,903 | 5,073 | 7,720 | 6,324 | 5,245 |
| Total assets | 37,357 | 32,540 | 25,148 | 20,618 | 20,636 | 18,266 | 16,733 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 320 | 201 | 112 | 1,160 | 1,305 | 39.10 | 113 |
| Net cash from operating activities | 4,660 | 4,225 | 3,450 | 5,053 | 1,339 | 3,514 | 1,839 |
| Net cash from investing activities | (5,760) | (5,697) | (3,429) | (3,403) | (1,990) | (1,454) | (1,689) |
| Net cash from financing activities | 1,117 | 1,591 | 68.10 | (2,697) | 506 | (794) | (224) |
| Net change in cash | 17.80 | 118 | 89.10 | (1,047) | (146) | 1,266 | (74.10) |
| Closing cash | 1,958 | 977 | 1,217 | 646 | 2,030 | 1,646 | 39.20 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -11.2% | +18.6% | +14.9% | +17.8% | +7.9% | +12.7% | - |
| EBITDA growth | -46.9% | +24.6% | +40.6% | +62.5% | -17.3% | +9.3% | - |
| PBT growth | -41.3% | +24.9% | +49.8% | +73.9% | -27.2% | +10.1% | +63.2% |
| Net income growth | -43.1% | +25.6% | +63.0% | +61.4% | -11.9% | -37.3% | - |
| Revenue CAGR (3Y) | +6.6% | +17.1% | +13.4% | +12.7% | +10.7% | +12.6% | +6.8% |
| EBITDA CAGR (3Y) | -2.4% | +41.7% | +23.6% | +13.7% | +4.1% | +33.1% | +18.0% |
| Profitability & leverage | |||||||
| Net income margin | +15.7% | +23.1% | +22.3% | +15.4% | +11.3% | +16.4% | +24.8% |
| Return on capital employed | +12.6% | +25.5% | +25.4% | +18.8% | +11.6% | +15.0% | +18.5% |
| Return on net worth | +10.7% | +20.2% | +19.4% | +13.5% | +9.2% | +11.5% | +21.1% |
| Debt / equity | 0.15 | 0.08 | 0.02 | 0.06 | 0.10 | 0.08 | 0.09 |
| Long-term debt / equity | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest cover | 5.47 | 1.73 | 0.44 | 0.51 | 2.14 | 2.03 | 2.30 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.05 | 1.36 | 1.24 | 1.19 | 1.12 | 1.18 | 1.19 |
| Inventory turnover | 4.31 | 5.38 | 5.52 | 5.31 | 4.67 | 5.33 | 5.63 |
| Debtors turnover | 4.07 | 4.37 | 4.37 | 3.67 | 3.19 | 3.06 | 2.84 |
| EPS (₹) | 38.56 | 64.14 | 260.31 | 156.83 | 97.55 | 131.39 | 176.76 |
| Dividend per share (₹) | 8.00 | 8.00 | 40.00 | 40.00 | 30.00 | 25.00 | 25.00 |
| Book value per share (₹) | 377.81 | 348.72 | 1,453.29 | 1,236.56 | 1,111.56 | 1,032.48 | 920.13 |
To see the full year-wise statements and ratios of Dr.Reddy's Laboratories Ltd, buy the company report.
Board of directors and KMP of Dr.Reddy's Laboratories Ltd
Dr.Reddy's Laboratories Ltd currently reports 11 directors and 2 key managerial personnel. 21 former directors have served the organization.
Current Directors and KMP
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kodumudi Pranatharthiharan Krishnan Also directs: Tata Consumer Products Limited, Asrec (India) Limited, Helios Trustee Private Limited and 3 more | Director | 07 Jan 2022 | 4 Years 9 Months | Current |
| Venkatanarasimham Mannam Also directs: Idea2enterprises (India) Private Limited, Dr. Reddy's Formulations Limited, DRL Impex Limited and 5 more | Cfo | 01 Aug 2024 | 2 Years 2 Months | Current |
| Leo Puri Also directs: Fortis Healthcare Limited | Director | 25 Oct 2018 | 7 Years 11 Months | Current |
| Erez Israeli Also directs: Aurigene Pharmaceutical Services Limited | Ceo | 01 Aug 2019 | 7 Years 2 Months | Current |
| Arun Madhavan Kumar | Director | 01 Aug 2022 | 4 Years 2 Months | Current |
| Satish Reddy Kallam Also directs: Aurigene Oncology Limited, Greenpark Hotels and Resorts Limited, Stamlo Industries Limited and 5 more | Whole-Time Director | 18 Jan 1993 | 33 Years 9 Months | Current |
Showing 6 of 13 current directors and KMP. View all directors and KMP
Peer comparison
Dr.Reddy's Laboratories Ltd is compared with the 6 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹54,543 Cr (FY 2025) | 9.0% | Vadodara, Gujarat, India | |||
| Dr.Reddy's Laboratories Ltdthis company | ₹33,700 Cr (FY 2026) | ₹4,007.16 Cr | 11.9% | 3.2% | 7,985 | Hyderabad, Telangana, India |
| Aurobindo Pharma Ltd | ₹32,346 Cr (FY 2025) | 9.0% | Hyderabad, Telangana, India | |||
| Cipla Limited | ₹28,409 Cr (FY 2025) | 7.0% | Mumbai, Maharashtra, India | |||
| Zydus Lifesciences Limited | ₹23,511 Cr (FY 2025) | 19.0% | Ahmedabad, Gujarat, India | |||
| Lupin Limited | ₹22,904 Cr (FY 2025) | 14.0% | Mumbai, Maharashtra, India | |||
| Intas Pharmaceuticals Limited | ₹21,241 Cr (FY 2025) | 7.0% | Ahmedabad, Gujarat, India |
To see the full peer comparison of Dr.Reddy's Laboratories Ltd, buy the company report.
Auditor
Dr.Reddy's Laboratories Ltd is audited by S.R. Batliboi & Associates LLP for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S.R. Batliboi & Associates LLP | FY 2024 | 101049W/E300004 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 26.60%, foreign institutional investors hold 20.70%, domestic institutional investors hold 43.10% and retail and other public shareholders hold 9.60%.
Sep 2026
QUARTER
26.60% Promoters
43.10% DII (Domestic Institutional)
20.70% FII (Foreign Institutional)
9.60% Retail & Others
Promoter holding - history
Now 26.60% · Sep 2026High 26.60% · Dec 2025Low 26.60% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 26.60% | 26.60% | 26.60% | 26.60% |
| Public | 73.40% | 73.40% | 73.40% | 73.40% |
Charges & borrowings
Open charges
₹34.23 Cr
Satisfied charges
₹586.71 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 02 Aug 1996 | 90135598 | Globaltrust Bank Ltd | ₹10 Cr | Open | |
| 19 Feb 1996 | 90132215 | Globaltrust Bank Ltd | ₹10 Cr | Open | |
| 20 Dec 1995 | 90135537 | Global Trust Bank Ltd | ₹5 Cr | Open | |
| 04 Dec 1995 | 90135533 | Global Trust Bank Ltd | ₹2.6 Cr | Open | |
| 06 Jul 1995 | 90132130 | Global Tust Bank Ltd | ₹5.5 Cr | Open |
To see the full charge records of Dr.Reddy's Laboratories Ltd, buy the company report.
Total charge records: 95 View all charges
Deals & funding
Dr.Reddy's Laboratories Ltd has 72 deals on record (61 market trades, 4 secondary share transfers, 4 acquisitions), with disclosed funding of ₹630 Cr; the latest was in September 2025.
Total deals
72
Market trades
61
Secondary share transfers
4
Acquisitions
4
Funding rounds
2
Disclosed funding
₹630 Cr
Deals on record (5 of 72)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Feb 2025 | Funding round | ₹30 Cr | Investors: Go Digit General Insurance Limited |
| Mar 2023 | Acquisition | ₹275 Cr | Buyer: Eris Lifesciences Limited Seller: Dr.Reddy's Laboratories Ltd |
| Jun 2022 | Acquisition | ₹98.3 Cr | Buyer: J B Chemicals and Pharmaceuticals Limited Seller: Dr.Reddy's Laboratories Ltd |
| Feb 2022 | Acquisition | Undisclosed | Buyer: Mankind Pharma Limited Seller: Dr.Reddy's Laboratories Ltd |
| Oct 2018 | Acquisition | Undisclosed | Buyer: Therapiva Private Limited Seller: Dr.Reddy's Laboratories Ltd |
To see the full deal history of Dr.Reddy's Laboratories Ltd, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Dr.Reddy's Laboratories Ltd has 730 court cases on record: 485 filed by Dr.Reddy's Laboratories, 247 filed against it. 192 cases are pending and 538 are disposed.
Total cases
730
Filed by the company
485
Filed against the company
247
Pending
192
Disposed
538
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 601 | 174 | 159 |
| District courts | 103 | 56 | 29 |
| Supreme Court | 22 | 14 | 2 |
| NCLAT | 3 | 3 | 2 |
| NCLT | 1 | 0 | 0 |
Cases on record (5 of 730)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Supreme Court | Court case | Filed against the company by M S Reddy Pharmaceuticals Limited Managing Director | Pending |
| High Court of Andhra Pradesh | Writ petition | Filed by the company against Eastern Power Distribution Company of Andhra Pradesh Limited (Apepdcl), and 1 other | Pending |
| High Court of Delhi | Court case (C.O. (COMM.IPD-TM)) | Filed by the company against Astrum Healthcare Pvt Ltd and Anr | Pending |
| High Court of Delhi | Commercial suit | Filed by the company against Zeelab Pharmacy Pvt. Ltd. | Pending |
| High Court of Delhi | Court case (C.O. (COMM.IPD-TM)) | Filed by the company against JBD Life Sciences Private Limited & Anr. | Pending |
To see the full case history of Dr.Reddy's Laboratories Ltd, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Dr.Reddy's Laboratories Ltd was last rated by Indiarating on 27 Dec 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Indiarating | 27 Dec 2021 |
To see the full credit ratings and regulatory alerts of Dr.Reddy's Laboratories Ltd, buy the company report.
MSME payment delays
Dr.Reddy's Laboratories Ltd has 102 MSME Form 1 returns on record between 2008 and 2024, listing 879 overdue payments to 93 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 93)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Shree Anantaa Inc | |||
| Dasha Pharmaceuticals Private Limited | |||
| Sekhmet Technologies Private Limited | |||
| Agile Infrastructure | |||
| Chemic Life Sciences Private Limited |
To see the full MSME payment records of Dr.Reddy's Laboratories Ltd, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Dr.Reddy's Laboratories has 9 subsidiary companies and 1 joint venture. This group structure data is as of FY 2022. The table lists each entity with its relationship and holding.
9
Subsidiary companies
1
Joint ventures
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Imperial Credit Private Limited | U06519TG1991PTC126383 | |
| Aurigene Discovery Technologies Limited | U24239KA2001PLC029391 | |
| Dr. Reddys Formulations Limited | U24299TG2021PLC149527 | |
| DRL Impex Limited | U65990TG1986PLC006695 | |
| Cheminor Investments Limited | U67120TG1990PLC010931 | |
| Dr. Reddys Bio-Sciences Limited | U72200TG2000PLC034765 |
To see the full group structure of Dr.Reddy's Laboratories Ltd, buy the company report.
Employees & EPFO
Dr.Reddy's Laboratories Ltd has a workforce of 7,985 employees on its EPFO records as of Nov 14, 2024, across 3 active EPFO establishments.
Employee count
7,985
Active EPFO establishments
3
Employee growth
7.14%
GST
Dr.Reddy's Laboratories has 35 GST registrations: 24 active and 11 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
35
Active
24
Cancelled / inactive
11
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAACD7999Q1ZL | Telangana | Active | 01 Jul 2017 |
| 36AAACD7999Q2ZK | Telangana | Active | 19 Jul 2017 |
| 02AAACD7999Q1ZW | Himachal Pradesh | Active | 01 Jul 2017 |
| 03AAACD7999Q1ZU | Punjab | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Dr.Reddy's Laboratories Ltd, buy the company report.
Recent activity
Dr.Reddy's Laboratories Ltd has 34 board changes on record since 1986: 13 appointments and 21 cessations. The latest: Srikanth Velamakanni was appointed as Additional Director on 01 Jul 2026.
AGM
Dr.Reddy'S Laboratories Ltd last Annual general meeting of members was held on 23 Jul 2026 as per latest MCA records.
Appointed
Srikanth Velamakanni was appointed as Additional Director.
Filing
Dr.Reddy'S Laboratories Ltd has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
Appointed
Venkatanarasimham Mannam was appointed as CFO.
Appointed
Sanjiv Soshil Mehta was appointed as Director.
Appointed
Alpna Hansraj Seth was appointed as Director.
Appointed
Claudio Dr Albrecht was appointed as Director.
Appointed
Arun Madhavan Kumar was appointed as Director.
Ceased
Bruce Leonard Andrews Carter ceased to be Director.
Ceased
Parag Agarwal ceased to be Nodal Officer.
Appointed
Penny Chan Wan was appointed as Director.
Appointed
Kodumudi Pranatharthiharan Krishnan was appointed as Director.
237 earlier events are in the company report.
News
Dr. Reddy's Laboratories: Co Gets DCGI Approval For Zytorvi® (Toripalimab) For Advanced Esophageal Squamous Cell Carcinoma; This Marks The Second Approved Use In India, Expanding Beyond Nasopharyngeal Carcinoma; Clinical Trials Indicate A 42% Decrease In Risk Of Disease Or Death.
DRREDDY: Rs. 24.65 Crores NSE Block Trade; for ~ 202,198 Shares, at Rs. 1219.00
Dr. Reddy's Laboratories: Co CFO Is Sure About "High-Teen" Revenue Growth For FY27 And Later; The Company Has The Ability To Acquire Up To $2B In "Strategic Assets" And Is Aiming To Buy Firms And Brands Across Various Therapies.
Dr Reddy's: CFO Expresses Interest In Acquiring Any Size Of Companies, Emphasizing The Importance Of The Right Assets.
Dr. Reddy's Laboratories: Unveils New Products To Boost Growth; Targets 25% EBITDA Margin Long-Term And 20% For FY27.
Dr Reddy's: Company's Co CFO Highlights Plans to Submit New PDT Applications in Emerging Markets; Nicotine Products Expected to Boost Sales in Europe by FY27.
From our blog
Frequently asked questions
Dr.Reddy's Laboratories is an active public limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 24 February 1984 (42+ years old) and is registered under CIN L85195TG1984PLC004507. Listed on BSE: 500124 and NSE: DRREDDY.
Dr.Reddy's Laboratories reported revenue of ₹33,700 Cr for FY 2025-26 (up 3.2% YoY) based on consolidated financials.
Dr.Reddy's Laboratories has 13 current directors and KMP:
- Venkateswara Prasad Gunupati - Managing Director
- Satish Reddy Kallam - Whole-Time Director
- Kodumudi Pranatharthiharan Krishnan - Director
- Leo Puri - Director
- Arun Madhavan Kumar - Director
- Srikanth Velamakanni - Additional Director
- Alpna Hansraj Seth - Director
- Claudio Dr Albrecht - Director
- Penny Chan Wan - Director
- Shikha Sanjaya Sharma - Director
- Sanjiv Soshil Mehta - Director
- Venkatanarasimham Mannam - Cfo
- Erez Israeli - Ceo
The latest financial statements of Dr.Reddy's Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 23 July 2026. Year-wise statements from 2015 are in the company report.
The GSTIN of Dr.Reddy's Laboratories is 36AAACD7999Q1ZL, registered in Telangana. The company has 35 GST registrations in all, of which 24 are active and 11 are cancelled or inactive. Other active GSTINs include 36AAACD7999Q2ZK (Telangana), 02AAACD7999Q1ZW (Himachal Pradesh), 03AAACD7999Q1ZU (Punjab).
The CIN (Corporate Identification Number) of Dr.Reddy's Laboratories is L85195TG1984PLC004507. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Dr.Reddy's Laboratories is a listed company as per MCA records. Its shares are listed on both BSE (code: 500124) and NSE (symbol: DRREDDY).
Dr.Reddy's Laboratories has 730 court cases on record: 485 filed by the company and 247 filed against it. 192 are pending. Most are in the high courts.
Dr.Reddy's Laboratories was incorporated on 24 February 1984, making it 42+ years old. It is registered with the Registrar of Companies, Hyderabad.
Dr.Reddy's Laboratories has 72 deals on record (61 market trades, 4 secondary share transfers, 4 acquisitions), with disclosed funding of ₹630 Cr; the latest was in September 2025.
The peers of Dr.Reddy's Laboratories by revenue are Sun Pharmaceutical Industries Limited, Aurobindo Pharma Ltd, Cipla Limited, Zydus Lifesciences Limited, Lupin Limited and 1 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Srikanth Velamakanni was appointed as Additional Director on 01 Jul 2026. Venkatanarasimham Mannam was appointed as CFO on 01 Aug 2024. Sanjiv Soshil Mehta was appointed as Director on 29 Dec 2023. Dr.Reddy's Laboratories has 34 board changes on record in total.